Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elanco Animal Health filings document the disclosures of a public animal health company focused on products for farm animals and pets. The record includes Form 8-K reports on operating results, clinical or regulatory matters, capital-structure updates, credit-facility amendments, investor presentations, and restructuring-related exit or disposal activities.
Elanco's proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards, and governance practices. Its filings also provide formal disclosure around material events, financial reporting, and the capital arrangements that support the company's global animal health operations.
Elanco Animal Health Inc. officer Rajeev A. Modi reported acquiring additional deferred stock units tied to the company’s common stock. On 12/12/2025, he acquired 66.4453 deferred stock units at a price of $21.29 per unit, increasing his directly held deferred stock units to 7,357.4821.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, with settlement following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc. reported an insider equity transaction by its president, CEO and director, Jeffrey N. Simmons. On 12/12/2025 he acquired 130.0723 deferred stock units at $ 21.29 per unit, increasing his holdings to 18,604.9984 deferred stock units, held directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation, reported an insider purchase of company stock. On December 11, 2025, he acquired 4,500 shares of Elanco common stock at a price of $21.33 per share.
After this transaction, Modi directly beneficially owns 123,082 Elanco shares. This total includes 1,579 shares acquired on January 31, 2025 and 205 shares acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.
Elanco Animal Health Inc. executive Robert M. VanHimbergen, the company’s EVP and CFO, reported buying 6,950 shares of common stock on December 11, 2025. The shares were purchased at a weighted average price of $21.6441 per share, with individual trades executed between $21.60 and $21.70 per share.
Following this transaction, he beneficially owns 124,233 shares of Elanco common stock held directly. The reported balance includes 7,426 shares that were previously reported but inadvertently omitted from his prior reported holdings.
Elanco Animal Health Inc. President, CEO and Director Jeffrey N. Simmons reported buying 22,000 shares of Elanco common stock on December 11, 2025. The shares were purchased in multiple transactions at a weighted average price of $21.7498 per share, with individual trade prices ranging from $21.739 to $21.75.
After this transaction, Simmons beneficially owned 167,000 shares held indirectly through a revocable trust and 1,802,380 shares held directly. The direct holdings include 1 share acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.
Elanco Animal Health announced a new restructuring plan focused on expanding profit margins, reshaping its global footprint, and funding more innovation. The plan includes a global headcount reduction of approximately 300 employees, along with about 300 additional roles that will be replaced by positions in growth areas or lower-cost geographies.
The company expects pretax charges of about $175 million, with roughly $130 million in cash-based costs, most to be paid over the next two years, and around $45 million in non-cash asset impairment charges. These impairments are mainly tied to closing its Kansas City, Missouri implant facility and exiting part of its Monheim, Germany facility.
In connection with its 2025 Investor Day, Elanco issued a press release reaffirming its fourth quarter and full-year 2025 guidance and discussing its innovation and financial outlook, as well as the restructuring actions.
Elanco Animal Health Inc. reported an insider equity transaction by its President, CEO and Director, Jeffrey N. Simmons. On 11/28/2025, Simmons acquired 119.0047 deferred stock units tied to Elanco common stock at a reference price of $23.27 per unit.
After this transaction, Simmons beneficially owned 18,474.9261 deferred stock units, held directly. Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent.
The units are part of the company’s Executive Deferral and Stock Match Plan and will settle in cash or shares after Simmons’ termination of employment or in a specified future year, according to the plan’s terms.
Elanco Animal Health executive Rajeev A. Modi reported an automatic award of deferred stock units tied to company stock. On 11/28/2025, he acquired 60.7916 deferred stock units at a reference price of $23.27. After this transaction, he beneficially owns 7,291.0368 derivative securities in the form of deferred stock units held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares of common stock after Modi’s employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan. Modi serves as Executive Vice President U.S. Pet Health and Global Digital Transformation, and this filing reflects his ongoing equity-based compensation.
Elanco Animal Health Inc. director Kapila K. Anand reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, Anand acquired 10,314 shares of Elanco common stock at a stated price of $0, reflecting a board compensation grant rather than a market purchase. After this grant, Anand beneficially owned 94,973 shares of Elanco common stock in direct ownership. The filing notes that this grant is part of the standard annual equity award program for non-employee members of the company’s Board of Directors.
Elanco Animal Health Inc. director reports equity grant. A non-employee member of Elanco’s Board of Directors reported receiving a grant of 10,314 shares of common stock on 11/28/2025 as an annual equity award, structured as deferred stock units with a stated price of $0 for reporting purposes. Following this award, the director beneficially owns 12,853 shares of Elanco common stock in direct ownership. The transaction was reported on a Form 4 as a routine board compensation grant.